{"entity":{"id":"nct06084416","kind":"trial","name":"A Study of Sovilnesib in Subjects With Ovarian Cancer","aka":[],"tldr":"A phase 1 trial of Sovilnesib run by Volastra Therapeutics, Inc., now recruiting.","summary":"A Study of Sovilnesib in Subjects With Ovarian Cancer is a phase 1 interventional study registered as NCT06084416 by Volastra Therapeutics, Inc., with 150 participants planned, started 2024-04-04, primary completion expected 2027-11. Conditions recorded: High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability. Interventions recorded: Sovilnesib.","status":"recruiting","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06084416","url":"https://clinicaltrials.gov/study/NCT06084416"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["high-grade-serous-ovarian-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["sovilnesib"],"companies":["volastra-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06084416","phase":"1","setting":"A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects With Selected Advanced Solid Tumors","sponsor":"Volastra Therapeutics, Inc.","enrolled":150,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06084416/","neighbours":{"cancer":[{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"}],"drug":[{"id":"sovilnesib","kind":"drug","name":"Sovilnesib","route":"/drugs/sovilnesib/"}],"company":[{"id":"volastra-therapeutics","kind":"company","name":"Volastra Therapeutics","route":"/companies/volastra-therapeutics/"}]}}